ArticleAAPS PharmSciTech2026
pH-Responsive Chitosan-Coated Spanlastic Nanovesicles for Enhanced Lung-Targeted Delivery of Brilliant Blue G in Acute Lung Injury.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lung injury (ALI) involves alveolar-capillary barrier disruption, inflammatory amplification, oxidative stress, and loss of alveolar architecture. This study developed pH-responsive chitosan-coated spanlastic nanovesicles as a pharmaceutical platform for lung-targeted delivery of Brilliant Blue G (BBG), a P2X7 receptor antagonist. BBG-loaded spanlastics were prepared by thin-film hydration and optimized using a 2³ factorial design assessing the effects of Span 60:BBG ratio, Span 60:edge activator ratio, and edge activator type on vesicle size, zeta potential, and entrapment efficiency. The optimized formulation was coated with chitosan to achieve surface cationization, enhance colloidal stability, support mucoadhesive interaction with lung tissue, and provide pH-responsive release. BBG-Ch-SPNs exhibited nanoscale size, positive zeta potential, high entrapment efficiency, acceptable hemocompatibility, and sustained drug release, with greater BBG liberation under acidic conditions relevant to inflamed lung microenvironments. Release kinetic analysis supported diffusion-controlled release with pH-dependent polymer relaxation, while stability testing confirmed preservation of vesicle size, surface charge, and drug entrapment over three months. In vivo, BBG-Ch-SPNs improved pulmonary retention and lung exposure compared with free BBG and uncoated spanlastics, demonstrating enhanced lung-targeting efficiency. Therapeutically, BBG-Ch-SPNs reduced BALF protein leakage, LDH activity, NOx levels, and leukocyte influx while preserving alveolar architecture and limiting septal thickening, edema, and inflammatory infiltration. These effects were accompanied by restored antioxidant defenses and suppression of P2X7R/NF-κB/NLRP3 inflammasome signaling. Overall, chitosan-coated spanlastics improved BBG formulation performance, pH-responsive delivery, pulmonary biodistribution, and therapeutic efficacy, supporting their potential as a targeted nanotherapeutic system for ALI.
Indexed as
Identifiers
42709297What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.